Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04208126

Early Versus Late Initiation of ECMO (Extracorporal Membrane Oxygenation) Trial (ELIEO-Trial)

This trial is a prospective randomized multicenter trial that assigns patients to either a treatment for Acute Respiratory Distress Syndrome (ARDS) with an Extracorporal Membrane Oxygenation (ECMO) immediately after admission to the intensive care unit or conservative treatment. The later can undergo ECMO following failure of conservative therapy as a rescue therapy. Patients will be included within 24 hours of the onset of symptoms of ARDS and will be randomized according to standard procedure. Follow-up will be performed until day 90 after study inclusion.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University hospital Tübingen

Tübingen, 72076, Germany

Location status: Recruiting

Location contact

Peter Rosenberger, Prof.

CONTACT

[email protected]

+49707129 ext. 86622

About this study

Patients suffering acute ARDS defined according to the Berlin Definition starting from severe stage with acute onset and (i) ratio partial arterial pressure of oxygen fraction of inspired oxygen inspired oxygen fraction (PaO2/ FiO2) ≤ 200 (ii) Bilateral opacities consistent with pulmonary edema on frontal chest radiograph, and (iii) requirement for positive pressure ventilation via an endotracheal tube or non-invasive ventilation (iv) no clinical evidence of left atrial hypertension, or if measured, a Pulmonary Arterial Wedge Pressure (PAOP) less than or equal to 18 mm Hg (v) less than 96 hours from onset of ARDS (vi) less than 7 days from the initiation of mechanical ventilation will be treated by ECMO either within 24 hours to referral to an ARDS ECMO center or as rescue therapy after failure of conventional therapy.

Outcome measures have been chosen according to robustness and sensitivity to change. They are of high clinical impact and reflect the treatment effect desired by clinicians.

Primary efficacy endpoint: All cause mortality by 90-days.

Key secondary endpoints are:

  • 28 day all cause mortality 3. SOFA Organ Failure Scores at day at day 1-7, 14, 28 and 90 days 4. Duration of mechanical ventilation support 5. ICU length of stay

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ARDS as defined according to the Berlin Definition1
  • The term "acute onset" is defined as follow: the duration of the hypoxemia criterion and the chest radiograph criterion must be ≤ 7 days at the time of randomization.
  • Patients must be enrolled within 96 hours of onset of ARDS and no later than 7 days from the initiation of mechanical ventilation.

Exclusion criteria

  • Age less than 18 years
  • More than 7 days since initiation of mechanical ventilation
  • more than 96 hours since meeting inclusion criteria
  • patient, surrogate or physician not committed to full intensive care support
  • pregnancy

Treatment and study plan

ECMO

Device

ECMO implantation immediately after ICU admission

Primary outcomes

  1. 90 day all cause mortality

    Time frame: 90 days after study inclusion

    90 day all cause mortality

Secondary outcomes

  1. Sepsis-related organ failure assessment score (SOFA) Organ Failure Scores

    Time frame: 1-14, 28 and 90 days after study inclusion

    SOFA Organ Failure Scores

  2. Duration of mechanical ventilation

    Time frame: within 90 days after study inclusion

    Duration of mechanical ventilation

  3. 28 day all cause mortality

    Time frame: 28 days after study inclusion

    28 day all cause mortality

  4. ICU length of stay

    Time frame: overall length of stay

    overall length of stay on ICU

Study contacts

Contact information is provided by the study sponsor or research team.

Peter Rosenberger, Prof.

CONTACT

[email protected]

+49707129 ext. 86622

Sponsors and collaborators

Lead sponsor

University Hospital Tuebingen

Other

Registry information

Official study title

Early Versus Late Initiation of ECMO Trial (ELIEO-Trial)

Acronym: ELIEO

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Dec 23, 2019
Registry last updated
May 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.